Latest Ratios: P/E Ratio 8.0x · EV/EBITDA 5.2x · ROE N/A. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.2B | $6.7B | $3.5B | $2.1B | $2.7B | $2.8B | $4.0B | $2.8B | $1.6B | $654M | $371M |
| Enterprise Value | $4.7B | $6.2B | $5.2B | $3.7B | $3.9B | $3.9B | $4.2B | $2.9B | $1.5B | $607M | $238M |
| P/E Ratio → | 8.01 | 9.76 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.99 | 3.88 | 4.30 | 2.20 | 3.92 | 5.21 | 10.58 | 9.21 | 6.04 | 3.36 | 4.49 |
| P/B Ratio | — | — | — | — | — | 1951.78 | 8.36 | 4.76 | 4.56 | 4.18 | 3.11 |
| P/FCF | 7.36 | 9.55 | — | — | — | — | — | — | — | — | — |
| P/OCF | 7.27 | 9.43 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.59 | 6.40 | 3.94 | 5.61 | 7.22 | 11.14 | 9.34 | 5.76 | 3.12 | 2.88 |
| EV / EBITDA | 5.23 | 6.94 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 5.46 | 7.32 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 8.85 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 95.9% | 92.9% | 93.0% | 93.6% | 94.0% | 95.0% | 96.0% | 95.2% | 97.6% | -42.2% |
| Operating Margin | 49.5% | 49.5% | -37.5% | -46.9% | -64.0% | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% |
| Net Profit Margin | 39.4% | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -216.7% | -81.4% | -53.2% | -50.5% | -57.2% | -68.0% |
| ROA | 29.6% | 29.6% | -20.2% | -34.8% | -30.7% | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.6% |
| ROIC | — | — | -32.2% | -39.9% | -35.0% | -31.6% | -48.8% | -39.7% | -44.9% | -100.1% | -491.7% |
| ROCE | 55.9% | 55.9% | -25.0% | -33.9% | -32.8% | -22.3% | -26.0% | -20.6% | -18.3% | -24.3% | -48.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 882.73 | 0.87 | 0.55 | 0.44 | 0.93 | 0.82 |
| Debt / EBITDA | 0.55 | 0.55 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | 750.80 | 0.44 | 0.07 | -0.21 | -0.30 | -1.12 |
| Net Debt / EBITDA | -0.55 | -0.55 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.70 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 5.58 | 5.58 | -1.17 | -4.39 | -5.47 | -5.03 | -6.15 | -18.21 | -9.20 | -5.32 | -15.96 |
Net cash position: cash ($985M) exceeds total debt ($492M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | 2.35 | 2.35 | 2.02 | 1.71 | 1.87 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 |
| Quick Ratio | 2.27 | 2.27 | 2.31 | 1.97 | 1.65 | 1.84 | 4.37 | 3.22 | 1.83 | 2.90 | 5.27 |
| Cash Ratio | 2.01 | 2.01 | 1.96 | 1.45 | 1.01 | 1.52 | 3.98 | 2.91 | 1.36 | 2.33 | 4.67 |
| Asset Turnover | — | 0.59 | 0.47 | 0.49 | 0.41 | 0.28 | 0.17 | 0.19 | 0.24 | 0.50 | 0.31 |
| Inventory Turnover | 0.90 | 0.90 | 2.47 | 2.14 | 2.05 | 2.04 | 1.01 | 0.63 | 0.79 | 0.43 | — |
| Days Sales Outstanding | — | 38.30 | 71.73 | 62.59 | 81.28 | 74.85 | 67.03 | 66.03 | 93.63 | 75.85 | 110.02 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 12.5% | 10.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 13.6% | 10.5% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $88M | $77M | $75M | $72M | $70M | $66M | $59M | $47M | $39M | $34M |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PTCT stock.
PTC Therapeutics, Inc.'s current P/E ratio is 8.0x. The historical average is 9.8x.
PTC Therapeutics, Inc.'s current EV/EBITDA is 5.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.9x.
Based on historical data, PTC Therapeutics, Inc. is trading at a P/E of 8.0x. Compare with industry peers and growth rates for a complete picture.
PTC Therapeutics, Inc. has 95.9% gross margin and 49.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
PTC Therapeutics, Inc.'s Debt/EBITDA ratio is 0.5x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Revenue volatility and one-time gains
Metrics are mathematically derived from official filings.
Lumpy Earnings Distort Valuation
PTCT's trailing P/E of 9.59 and EV/EBITDA of 6.36 appear optically cheap, but forward P/E of 56.20 suggests the market prices in normalized earnings, per reported figures.
The trailing multiples are artificially depressed by the one-time gain in 2025Q1 that inflated net income, while the forward P/E implies the market expects a sharp earnings decline from that peak. This wide gap between trailing and forward multiples indicates that investors are not paying for the spike but for a sustainable earnings base, which has yet to be demonstrated. The EV/EBITDA of 6.36 is below the peer median, but given the erratic EBITDA, this multiple may not be meaningful without normalizing for non-recurring items.
Margin Volatility Masks Core Economics
Gross margin swung from 45.1% in 2025Q3 to 93.6% in 2025Q2, while operating margin ranged from -49.6% to 41.3% in 2026Q2, per financial statements.
The extreme margin swings suggest that reported profitability is heavily influenced by one-time items and product mix shifts, rather than a stable operating model. The 41.3% operating margin in 2026Q2 appears to be an outlier, as prior quarters show negative operating margins, indicating that the company's core operations may not be consistently profitable. Investors should focus on normalized margins excluding non-recurring gains, as the current figures do not reflect sustainable earning power.
Return on Capital Remains Elusive
ROIC was -20.5% in 2024Q4, and ROA has been negative in most quarters, with only 2025Q1 showing a 39.7% spike, per reported data.
The negative ROIC and ROA in most periods indicate that the company has not been generating returns above its cost of capital on a consistent basis. The 2025Q1 spike is likely due to a one-time gain, not operational improvement. The lack of consistent positive returns suggests that the company is still in a phase of heavy investment or facing structural profitability challenges, which may warrant a discount in valuation.
Working Capital Cycles Swing Wildly
Cash conversion cycle swung from 58 days in 2026Q2 to 249 days in 2025Q4, driven by DSO ranging from 14 to 107 days, per SEC filings.
The extreme volatility in DSO and CCC suggests that revenue recognition and collection patterns are highly irregular, possibly due to lumpy product sales or milestone payments. The negative DPO in some quarters (e.g., -81 in 2026Q1) indicates that the company is paying suppliers faster than it collects from customers, which could strain liquidity if sustained. This inefficiency in working capital management may be a result of the company's business model, but it adds to cash flow unpredictability.
Debt Coverage Improves but Remains Thin
Interest coverage improved to 3.07 in 2026Q2 from negative levels in prior quarters, while D/EBITDA fell to 4.68, per reported figures.
The improvement in interest coverage and D/EBITDA in 2026Q2 is encouraging, but it is based on a quarter with unusually high operating income. In prior quarters, interest coverage was negative, indicating that the company could not service its debt from operating earnings. The debt level of $696.5M is substantial relative to the company's market cap, and the negative equity position means that traditional leverage ratios are not meaningful. Investors should monitor whether the 2026Q2 profitability is sustainable, as it is the sole support for the improved coverage.
Liquidity Buffer Holds Despite Volatility
Current ratio improved to 3.39 in 2026Q2 from 2.03 in 2024Q1, with cash of $1.0B exceeding total debt of $696.5M, per balance sheet data.
The liquidity position appears adequate, with a current ratio above 3 and a quick ratio of 3.28, indicating that the company can cover short-term obligations without relying on inventory. However, the negative equity of -$165.4M suggests that the company is dependent on external financing or cash reserves to sustain operations. The cash buffer provides a cushion, but the erratic cash flows could quickly erode it if the company faces a prolonged period of negative operating cash flow.
P/E Misleads on One-Time Gains
The trailing P/E of 9.59 is misleading because it is based on a quarter with a one-time gain, obscuring the company's true earnings power, per reported data.
The most commonly misapplied ratio for PTCT is the P/E, as the trailing earnings include a massive one-time gain in 2025Q1 that is not indicative of ongoing profitability. Using the trailing P/E would suggest the stock is undervalued, but the forward P/E of 56.20 reveals that the market is pricing in a much lower earnings base. Investors should use a normalized P/E that excludes non-recurring items, or rely on EV/EBITDA with adjusted EBITDA, to get a clearer picture of valuation. The company's negative equity also makes P/B meaningless, so alternative metrics like EV/Sales or EV/EBIT on a normalized basis are more appropriate.